8:00 - 8:10 am  Welcome and Approval of 2014 Spring Meeting Minutes  T. Petrella

8:10 - 9:00 am  Trial Updates

- MEC.3 - A Phase III Randomized Study of Adjuvant Iplimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG)  T. Petrella

- ME.12 - Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma  T. Petrella

- MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance)  A. Joshua

- IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases  T. Petrella

- ME11 - Adjuvant Pegylated-Interferon-alpha2b (Sylatron™) for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group  A. Spatz

9:00 - 10:00 am  New Proposals

- A phase III randomized trial comparing high dose interferon alpha-2b to MK-3475 (pembrolizumab) in patients with high risk resected melanoma - SWOG S1404  T. Petrella

- Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma - ECOG EA6141  T. Petrella
MELANOMA DISEASE SITE AGENDA

9:00 - 10:00 am  New Proposals Continued

- Autoantibodies against immune checkpoints: a putative mechanism to account for long term survival following spontaneous regression of metastatic melanoma  C. Lee
- Translational proposal  A. Spatz
- Assessment of response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker  T. Petrella
- Adjuvant mucosal melanoma trial  T. Petrella
- Neoadjuvant proposal  X. Song

10:00 - 10:15 am  Break

10:15 - 11:00 am  New Proposals Continued

- Reolysin and Immune Checkpoint Inhibitors: Rational for the Combination  G. Selvaggi
- Reolysin Proposal in Melanoma  J. Monzon

11:00 - 12:00 pm  Melanoma Site Strategic Planning
(NCIC CTG Members Only)

- Background  J. Dancey
- Discussion  T. Petrella

12:00 pm  Meeting Adjourned

12:15 - 1:00 pm  Executive Committee meeting to follow (closed)